• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Idera Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010 Product Image

Idera Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • 70 pages
  • GlobalData

Idera Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Idera Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Idera Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Idera Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including READ MORE >



List of Tables
List of Figures
Idera Pharmaceuticals, Inc. Snapshot
Idera Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Idera Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Idera Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Idera Pharmaceuticals, Inc. – Pipeline Products Glance
Idera Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Idera Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Idera Pharmaceuticals, Inc. – Drug Profiles
GEM231
Product Description
Mechanism of Action
R&D Progress
IMO-2055 + Erbitux + Camptosar
Product Description
Mechanism of Action
R&D Progress
IMO-2125
Product Description
Mechanism of Action
R&D Progress
IMO-2125 + Ribavirin
Product Description
Mechanism of Action
R&D Progress
IMO-2134
Product Description
Mechanism of Action
R&D Progress
Dual TLR7/8 Agonists for Oncology
Product Description
Mechanism of Action
R&D Progress
GEM240
Product Description
Mechanism of Action
R&D Progress
IMO-3100
Product Description
Mechanism of Action
R&D Progress
TLR7 Agonists
Product Description
Mechanism of Action
R&D Progress
TLR7, 8, and 9 Agonists
Product Description
Mechanism of Action
R&D Progress
Dual TLR7/8 Agonists for Infectious Diseases
Product Description
Mechanism of Action
R&D Progress
TLR7 Agonists
Product Description
Mechanism of Action
R&D Progress
TLR8 Agonists
Product Description
Mechanism of Action
R&D Progress
TLR8 Agonists for Infectious Diseases
Product Description
Mechanism of Action
R&D Progress
Idera Pharmaceuticals, Inc. – Pipeline Analysis
Idera Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Idera Pharmaceuticals, Inc. Pipeline Products By Target
Idera Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Idera Pharmaceuticals, Inc. – Recent Pipeline Updates
Idera Pharmaceuticals, Inc. – Company Statement
Idera Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 17, 2010: Idera Presents Preclinical Data On Mechanism Of Action Of TLR Antagonist Candidate In Model Of Hyperlipidemia At AHA Meeting
Nov 09, 2010: Idera Presents Preclinical Data From Autoimmune Disease Program At ACR 74th Annual Scientific Meeting
Nov 09, 2010: Idera Presents Preclinical Data From Autoimmune Disease Program At ACR 74th Annual Scientific Meeting
Oct 30, 2010: Idera Presents Phase I Data On IMO-2125 Demonstrating Induction Of Broad Antiviral Immune Response In Null-Responder HCV Patients At AASLD Meeting 2010
Oct 29, 2010: Idera Announces Data Presentation Of Toll-Like Receptor 3 Agonist Compounds At Immunological Mechanisms Of Vaccination Keystone Meeting
Oct 21, 2010: Idera Announces Phase I Clinical Results Of IMO-3100 For Treatment Of Autoimmune Diseases
Oct 21, 2010: Idera Announces Phase I Clinical Results Of IMO-3100 For Treatment Of Autoimmune Diseases
Oct 01, 2010: Idera Presents IMO-2125 Data For Treatment Of HCV Infection At AASLD Annual Meeting
Aug 27, 2010: Idera Achieves Clinical Milestone Under Collaboration With Merck KGaA For Cancer Treatment
Aug 27, 2010: Idera Achieves Clinical Milestone Under Collaboration With Merck KGaA For Cancer Treatment
Financial Deals Landscape
Idera Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Idera Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Idera Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Idera Pharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
Idera Pharmaceuticals Completes Private Placement Of $10 Million
Idera Pharmaceuticals Completes Private Placement Of $4 Million
Idera Pharmaceuticals Completes Private Placement Of $3.5 Million
Idera Pharmaceuticals Completes Private Placement Of $9.75 Million
Debt Offering
Idera Pharmaceuticals Completes Private Placements Of Convertible Notes For $5 Million
Idera Pharmaceuticals Extends Research Collaboration Agreement With Merck
Idera Pharmaceuticals Extends Its Agreement With Merck
Idera Pharmaceuticals Extends Its Agreement With Novartis
Idera Pharmaceuticals Enters Into An Agreement With Merck
Idera Pharmaceuticals To Terminate Research Collaboration Agreement With Novartis
Licensing Agreements
Idera Pharmaceutical Enters Into Licensing Agreement With Merck
Merck Signs An Agreement With Idera Pharmaceuticals
Alnylam Enters Into License Agreement With Hybridon
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS